Get the Stockscreener App
5.46
8.12%
0.41
Pre-market:
5.34
-0.12
-2.20%
Savara Inc stock is traded at $5.46, with a volume of 1.84M.
It is up +8.12% in the last 24 hours and down -9.30% over the past month.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
See More
Previous Close:
$5.05
Open:
$5.12
24h Volume:
1.84M
Relative Volume:
1.12
Market Cap:
$1.12B
Revenue:
-
Net Income/Loss:
$-118.84M
P/E Ratio:
-10.22
EPS:
-0.5344
Net Cash Flow:
$-101.06M
1W Performance:
+8.33%
1M Performance:
-9.30%
6M Performance:
+52.94%
1Y Performance:
+97.11%
1-Day Range:
$5.12
$5.48
1-Week Range:
$4.85
$5.48
52-Week Range:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.46 | 1.12B | 0 | -118.84M | -101.06M | -0.5344 |
VRTX
Vertex Pharmaceuticals Inc
|
446.54 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
772.64 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
730.25 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.87 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.52 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Citizens reiterates Savara stock rating on regulatory progress By Investing.com - Investing.com India
Citizens reiterates Savara stock rating on regulatory progress - Investing.com
EMA validates Savara’s MOLBREEVI application for autoimmune PAP By Investing.com - Investing.com Australia
Savara (SVRA) MAA Submission in Europe Receives Validation - GuruFocus
Jefferies reiterates Savara stock Buy rating on approval confidence By Investing.com - Investing.com India
Jefferies sees Savara stock approval odds at 90% for rare lung drug - Investing.com
Jefferies reiterates Savara stock Buy rating on approval confidence - Investing.com
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
Savara : Corporate Presentation - marketscreener.com
Savara Inc announced that its Marketing Authorization Application (MAA) for Molbreevi*, a treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), has been formally validated by the European Medicines Agency (EMA). - Bitget
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
Rare lung disease drug enters EMA review, with EU decision due Q1 2027 - Stock Titan
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Savara grants inducement equity awards to new employee - MSN
Death Cross: Whats the fair value of Savara Inc stockTrade Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
Savara’s MOLBREEVI BLA Receives FDA Priority Review - msn.com
FDA to review Savara resubmitted Molbreevi BLA - MSN
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval - MyChesCo
Savara Inc devrait afficher une perte de 12 cents par actionEarnings AVANT-PAPIER - TradingView
Aug Big Picture: What is the Moat Score of Savara IncNew Guidance & Stock Market Timing Techniques - baoquankhu1.vn
Savara (SVRA) CFO exercises stock options and ends with 536,032 shares - Stock Titan
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Will Advancing MOLBREEVI and a New HQ Lease Change Savara's (SVRA) Narrative? - simplywall.st
Weekly Earnings: Can Savara Inc withstand a market correctionGDP Growth & Proven Capital Preservation Tips - baoquankhu1.vn
FY2026 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
Lifesci Capital Analysts Lift Earnings Estimates for Savara - MarketBeat
HC Wainwright Comments on Savara's Q1 Earnings (NASDAQ:SVRA) - MarketBeat
Savara says FDA review of MOLBREEVI to proceed without advisory committee - MSN
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch - streetwisereports.com
Growth Report: Will Savara Inc announce a stock splitForecast Cut & High Accuracy Swing Entry Alerts - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Savara Inc. (SVRA) March 2026 - Meyka
H.C. Wainwright reiterates Savara stock rating, $10 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Savara stock rating, $10 target - Investing.com
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com - Investing.com Nigeria
Savara Inc. $SVRA Stake Cut by Farallon Capital Management LLC - MarketBeat
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):